Rose Marie Holman
Publications by Year
Research Areas
Immunotherapy and Immune Responses, RNA Interference and Gene Delivery, vaccines and immunoinformatics approaches, Nanoplatforms for cancer theranostics, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant(2008)244 cited
- → Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma(2015)91 cited
- → Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma(2019)71 cited
- → Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid–poly-l-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy(2014)10 cited
- → Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.(2012)5 cited
- → Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma(2013)4 cited
- → Tanderil®/Chloramphenicol Eye Ointment in the Treatment of the “Red Eye” Seen in General Practice(1978)4 cited
- → Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.(2014)3 cited
- → Treatment of solid tumors with intratumoral poly-ICLC: A phase II clinical study.(2014)1 cited